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Due to the availability of cervical cytology screening programmes,
the incidence of invasive cervical cancer is decreasing.
Nevertheless, invasive cervical cancer remains a major health
concern throughout the world. Disease stage is the most significant
prognostic criterion in individuals presenting with invasive
cervical cancer; however, patient survival following radical
hysterectomy and pelvic lymphadenectomy is dependent on
several factors. These factors include status of the lymph nodes,
tumour size, paracervical involvement, depth of stromal invasion
and lymph vascular space invasion (Lurain, 1996). The most
highly dependent variable associated with survival is lymph node
status. In fact, a favourable survival rate (5-year, disease-free
survival, 87.9%) has been observed in patients displaying negative
pelvic nodes, whereas a survival rate of 48.7% has been
documented in patients demonstrating nodal involvement in our
hospital (Kodama et al, 1999a). However, the mechanisms relating
to lymph node metastasis are poorly examined. 
It is well known that vascular endothelial growth factor (VEGF)
plays an essential role in vasculogenesis and angiogenesis. In a
previous study, we showed that VEGF expression is involved in
the promotion of angiogenesis in cervical cancer (Kodama et al,
1999b). Several additional members of the VEGF family have
been identified, including placenta growth factor (P1GF), VEGF-
B, VEGF-C, VEGF-D and VEGF-E (Maglione et al, 1991; Kukk
et al, 1996; Olofsson et al, 1996; Yamada et al, 1997; Meyer et al,
1999). VEGF-C binds to and induces autophosphorylation of the
tyrosine kinase receptor VEGFR-3. VEGF-C also activates
VEGFR-2 but not VEGFR-1 (Kukk et al, 1996). Other members
of the VEGF family, with the exception of VEGF-D, are unable to
activate VEGFR-3. VEGFR-3 is highly specific to the lymphatic
endothelium in adult tissues (Kaipainen et al, 1995). Con-
sequently, VEGF-C and VEGFR-3 have been implicated in
lymphangiogenesis. 
Recently, the correlation of VEGF-C expression in malignant
tumours with lymph node metastasis has been reported (Bunono
et al, 1999; Kurebayashi et al, 1999; Tsurusaki et al, 1999;
Yonemura et al, 1999; Akagi et al, 2000). No investigations have
been conducted regarding VEGF-C expression in invasive cervical
cancer. The current study examined VEGF-C mRNA expression
in invasive cervical cancer tissues as well as its association with
clinicopathological features. A meaningful correlation between
VEGF-C expression and pelvic lymph node metastasis was
confirmed. 
MATERIALS AND METHODS 
Patients and tissue samples 
The patient population for this study consisted of 75 individuals
presenting with invasive cervical cancer (Department of Obstetrics
and Gynecology of Okayama University Medical School,
Okayama, Japan). Biopsy specimens were obtained prior to the
initiation of treatment. Each specimen was partitioned into 2 equal
portions. One sample was snap frozen and stored at –80˚C until
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10% formaldehyde solution for histopathologic examination.
Specimens that did not display significant cancer cell numbers
upon histopathological diagnosis were excluded from the study.
Magnetic resonance (MR) imaging was performed on a 1.5-T
superconducting magnet (Magnetom H-15; Siemens, Erlangen,
Germany) in order to evaluate tumour size, local extension and
lymph node metastasis. 
Histologic cell types of the tumours were assigned according to
the WHO classification. 40 cases were classified as squamous cell
carcinoma, 22 as adenocarcinoma and 13 as adenosquamous carci-
noma. Staging was reviewed based on the International Federation
of Gynecology and Obstetrics (FIGO) staging system: 23, 38, 10
and 4 cases were stage Ib, stage II, stage III and stage IV, respec-
tively. Median age at the time of treatment was 53 years (range
26–90 years). Radical hysterectomy and pelvic lymphadenectomy
were performed in 53 subjects with stage Ib–IIb disease but other-
wise exhibiting good physical condition. Patients displaying
lymph node metastasis, parametrial involvement, deep stromal
invasion or marked lymph–vascular space involvement were
treated with adjuvant external whole pelvic irradiation (50 Gy) or
adjuvant combination chemotherapy. The remaining 22 patients
were treated primarily with radiotherapy or concurrent chemora-
diotherapy. Disease-free survival was defined as the interval from
initial therapy to the recurrence or to November 30, 2000. The
median duration of follow-up was 28 months (range, 3–59).
Disease recurred in 24 out of 75 subjects (32.0%). Additionally, 10
normal cervical specimens were obtained from patients demon-
strating benign gynaecological disease. 
RNA preparation of sample 
Total RNA was prepared from each specimen using an RNeasy Total
RNA kit (QIAGEN, Hilden, Germany) according to the manufac-
turer’s protocol. Tissues exhibiting RNA characterized by high
quality 18S and 28S bands on ethidium bromide-stained gels were
preferentially selected. 
Reverse transcriptase-polymerase chain reaction 
RT was conducted according to the Thermoscript RT-PCR System
(LIFE TECHNOLOGIES, Rockville, MD) protocol for reverse
transcription of 3 ug total RNA in a total 20 ul reaction volume.
Transcribed products were subjected to PCR for VEGF-C (sense
primer; 5¢-GAGGCTGGCAACATAACAGAG-3¢, antisense primer;
5¢-CCTTGAGAGAGAGGCACTGT-3¢) and b-actin (sense primer;
5¢-CTCACCATGGATGATGATAT-3¢, antisense primer; 5¢-TGG-
GTCATCTTCTCGCGGTT-3¢) (Fujita et al, 1994; André et al,
2000). VEGF-C cDNA amplification was initiated with denatura-
tion for 3 min at 94˚C followed by 30 cycles of 30-s denaturation
at 94˚C. Annealing was then effected at 59˚C for 1 min followed
by a 1 min extension at 72˚C. The PCR profile for b-actin
consisted of an initial denaturation of 3 min at 94˚C followed by
30 cycles of 1-min denaturation at 94˚C, 1-min annealing at 55˚C
and a 1-min extension at 72˚C. The PCR mixture was maintained
at 72˚C for 15 min for final extension. The details of PCR reaction
mixture have been described elsewhere (Seki et al, 1997). Final
PCR products were subsequently electrophoresed on a 2% agarose
gel and stained with ethidium bromide. UV-illuminated gels were
photographed using Polaroid Type 667 films. Photographs were
quantitated with an image scanner GT-9500 (EPSON, Suwa, Japan)
and analysed with Basic Quantifier software (Bio Image, Ann
Arban, MI). 
cDNA amounts were corrected by b-actin as an internal stan-
dard in order to obtain semi-quantification of VEGF-C mRNA
levels. For this reason, a technique based on a competitive PCR
approach involving a nonhomologous internal standard was
employed (COMPETITOR; Competitive DNA Construction Kit;
TAKARA, Kyoto, Japan). 1 ul cDNAs derived from samples were
co-amplified in the presence of serial dilutions of b-action
COMPETITOR. The point of equal intensity between the bands of
b-actin COMPETITOR and the cDNA template was evaluated.
cDNAs in the presence of 1 ´ 105 copies of b-actin were subse-
quently utilized in the amplification of VEGF-C gene. PCR prod-
ucts derived from VEGF-C gene were assigned to the positive (+)
or negative (–) VEGF-C expressing groups. 
Immunohistochemical staining for microvessels 
Expression of factor VIII-related antigen was assessed in 53
formalin-fixed, paraffin-embedded sections obtained at the time of
radical surgery by the avidin-biotin complex (ABC) procedure.
Anti-factor VIII-related monoclonal antibody (DAKOPATTS,
Copenhagen, Denmark) was utilized as a primary antibody. The
entire tumorous lesion was scanned under low-power magnifica-
tion in order to select regions displaying the most intense vascular-
ization. The number of microvessels was recorded by counting any
positively stained endothelial cell or endothelial cell cluster as a
single, countable microvessel in a 100 ´ microscopic field. In most
cases, the microvessel density was higher at the invasive edge of
the tumour than within the tumour. The 10 most neovascularized
regions were selected as a minimum. The mean of the top 3 counts
was used as the microvessel count for each case. Microvessel
number was determined by an investigator who had no knowledge
of the VEGF-C expression. 
Statistical analyses 
Association between the variables were tested using the Chi-
square test, Fisher’s exact probability test, Mann–Whitney U-test
or stepwise logistic regression analysis. Survival rates were calcu-
lated by the Kaplan–Meier method and differences were examined
by the log-rank test. Factors found to be significant were then
chosen for stepwise Cox’s multivariate proportional hazard model
in order to ascertain their prognostic values. These analyses were
performed utilizing the Stat-View 5.0 software (Abacus Concepts,
Berkeley, CA). Probability values less than 0.05 were considered
statistically significant. 
RESULTS 
VEGF-C mRNA expression in normal cervix and
cervical cancer 
Figure 1 displays representative photographs of the final RT-PCR
products for VEGF-C in normal cervix (cases 1–3) and invasive
cervical cancer (cases 4–10). VEGF-C mRNA expression was
detected in only 1 of 10 normal cervical specimens (10.0%). In
contrast, VEGF-C mRNA expression was detected in 36 of 75
invasive cervical cancer samples (48.0%). The frequency of
detectable VEGF-C mRNA of invasive cervical cancer was
markedly higher than that of normal cervix (P = 0.017). 
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higher in tumours exhibiting pelvic lymph node metastasis as-
sessed by MR imaging (P = 0.002) (Table 1). No meaningful dif-
ferences in VEGF-C mRNA expression with respect to age,
histological cell type and clinical stage were observed. 
VEGF-C mRNA expression and clinicopathological
features in cervical cancer treated with radical
hysterectomy and pelvic lymphadenectomy 
The frequency of detectable VEGF-C mRNA was significantly
higher in tumours exhibiting deep stromal invasion, pelvic lymph
node metastasis and lymph–vascular space involvement (P =
0.016, P = 0.006 and P = 0.036, respectively) (Table 2). There was
no correlation between VEGF-C mRNA expression and other clin-
icopathological factors (Table 2). The mean microvessel counts in
tumours exhibiting and lacking VEGF-C mRNA expression were
37.5 ± 4.8 and 37.4 ± 5.3, respectively (not significant). 
Pelvic lymph node metastasis was correlated with tumour size,
stromal invasion, parametrial invasion, lymph–vascular space
involvement and VEGF-C mRNA expression. Multivariate
analysis revealed VEGF-C mRNA expression to be the exclusive
independent factor influencing pelvic lymph node metastasis
(Table 3). As a result, VEGF-C mRNA expression was further
compared with MR imaging in the evaluation of pelvic lymph
node metastasis. Sensitivity, specificity, positive and negative
predictive values and accuracy of VEGF-C mRNA expression and
MR imaging in the diagnosis of pelvic lymph node metastasis
were 81.3%, 62.2%, 48.1%, 88.5%, 67.9% and 43.8%, 100%,
100%, 80.4%, 83.0%, respectively. 
Association of VEGF-C mRNA expression with survival 
Figure 2A presents the disease-free survival curves of patients in 75
patients displaying invasive cervical cancer according to the VEGF-
C mRNA expression status. A tendency between VEGF-C mRNA
expression and poorer outcome was noted; however, the relation-
ship was not statistically significant (P = 0.068). Figure 2B shows
the disease-free survival curves in 53 instances of invasive cervical
cancer treated with radical hysterectomy and pelvic lymphadenec-
tomy. Patients exhibiting VEGF-C mRNA expression demonstrated
a markedly poorer prognosis than those lacking VEGF-C mRNA
expression (P = 0.049). Deep stromal invasion, parametrial inva-
sion, lymph–vascular space involvement, pelvic lymph node metas-
tasis and high microvessel count were also found to be significant in
disease-free survival. Microvessel count was an only independent
prognostic factor in the multivariate proportional hazard model. 
DISCUSSION 
In the present study, VEGF-C mRNA expression in normal cervix
and invasive cervical cancer specimens was investigated. We
showed that the frequency of detectable VEGF-C mRNA of inva-
sive cervical cancer is significantly higher than that of normal
cervix. This finding is consistent with other reports, which demon-
strated elevated VEGF-C expression in tumour tissues in contrast
to the low levels observed in the normal tissues (Bunone et al,
1999; Ohta et al, 1999; Valtola et al, 1999; Yonemura et al, 1999;
Akagi et al, 2000). Consequently, we hypothesize that VEGF-C
VEGF-C expression in cervical cancer 95
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Figure 1 Detection of mRNA for VEGF-C in normal cervix and invasive
cervical cancer. Total RNAs from biopsy specimens were extracted,
transcribed to cDNAs and subjected to PCR for VEGF-C. Cases 1–3; normal
cervix, cases 4–10; invasive cervical cancer 
Table 1 Association between VEGF-C mRNA expression and
clinicopathological factors in cevical cancer 
VEGF-C 
No. of cases
(+) (–) 
P value 
Age 
<50 37 22 15 NS 
³50 38 14 24 
Histological cell type 
SCC 53 28 25 NS 
ADE 22 8 14 
Stage 
I+II 61 29 32 NS 
III+IV 14 7 7 
Pelvic lymph node statusa
negative 61 24 37 P = 0.002 
positive 14 12 2 
SCC, squamous cell carcinoma; ADE, adenocarcinoma; a pelvic lymph node
status assessed by MR imaging; NS, not significant. 
Table 2 Association between VEGF-C mRNA expression and
clinicopathological factors in cervical cancer treated with radical
hysterectomy and pelvic lymphadenectomy 
VEGF-C 
Variables No. of cases
(+) (–)
P value
Age NS
< 50 34 19 15
³ 50 19 8 11
Histological cell type NS
SCC 34 20 14
ADE 19 7 12
Tumour size (cm) NS
≤ 43 8 1 9 1 9
> 4 15 8 7
Stromal invasion P = 0.016
≤ 2/3 20 6 14
> 2/3 33 21 12
Parametrial invasion NS 
Negative 33 14 19 
Positive 20 13 7 
Vaginal invasion NS 
Negative 44 22 22 
Positive 9 5 4 
Lymphnode metastasis P = 0.006 
Negative 37 14 23 
Positive 16 13 3 
LVS involvement P = 0.036 
Negative 21 7 14 
Positive 32 20 12 
SCC, squamous cell carcinoma; ADE, adenocarcinoma; LVS, lymph-vascular
space; NS, not significant. may contribute to the metastatic process, carrying cancer cells into
the lymphatic vessels. 
VEGF-C mRNA expression was further examined so as to
determine correlation with clinicopathological features in invasive
cervical cancer. The current results clearly demonstrated that the
frequency of detectable VEGF-C mRNA was markedly increased
in cases where lymph–vascular space involvement and pelvic
lymph node metastasis were in evidence. The present data are
compatible with reports that positive correlation between VEGF-C
expression and lymphatic invasion was observed in cases of colon
cancer, gastric cancer and lung adenocarcinoma (Yonemura et al,
1999; Akagi et al, 2000; Niki et al, 2000). A meaningful correla-
tion between VEGF-C expression and lymph node metastasis has
been reported in cases of colon cancer, prostatic carcinoma, breast
cancer, gastric cancer and thyroid cancer (Bunono et al, 1999;
Kurebayashi et al, 1999; Tsurusaki et al, 1999; Yonemura et al,
1999; Akagi et al, 2000). These findings indicate that VEGF-C
expression is implicated in lymphatic invasion and lymph node
metastasis. Although lymphatic vessel counts were not measured
in this study, several investigations showed a close correlation
between VEGF-C and VEGFR-3 expression (Tsurusaki et al,
1999; Gunningham et al, 2000; Yonemura, 1999). We postulate
that VEGF-C stimulates lymphangiogenesis and enhances the
invasion of cancer cells via loosing of lymphatic endothelial cells,
resulting in lymph node metastasis. 
Lymphangiography (LAG), computed tomography (CT) or
magnetic resonance (MR) imaging were employed in the diag-
nosis of lymph node metastasis in patients presenting with inva-
sive cervical cancer. The LAG, CT and MR imaging provide
similar performance in the detection of lymph node metastasis
derived from cervical cancer (Scheidler et al, 1997). MR imaging
has been commonly utilized in the evaluation of invasive cervical
cancer in our hospital. Interestingly, multivariate analysis revealed
that VEGF-C mRNA expression in biopsy specimens is the sole
independent factor influencing pelvic lymph node metastasis in
the present study. Therefore, MR imaging was compared with
VEGF-C mRNA expression in the evaluation of pelvic lymph
node metastasis. A trend toward higher accuracy was displayed by
MR imaging relative to that for VEGF-C mRNA expression.
However, it is noteworthy that VEGF-C mRNA expression offered
markedly higher sensitivity in the detection of pelvic lymph node
metastasis. 
Determination of the identity of angiogenic factors involved
in the mediation of angiogenesis is of paramount importance.
Consequently, this information could afford novel methods for
therapeutic intervention in this disease. In a previous study, we
showed that the expression of VEGF-A is involved in the promo-
tion of angiogenesis in cervical cancer (Kodama et al, 1999b).
VEGF-C is a ligand for VEGFR-2; therefore, we examined the
correlation between VEGF-C mRNA expression and vasculariza-
tion in cervical cancer. Our study demonstrated that VEGF-C gene
expression is not correlated with tumour vascularity in inva-
sive cervical cancer. In accordance with our report, VEGF-C gene
or protein expression is reported not to be correlated with
microvessel count in colorectal cancer, mesothelioma, prostatic
carcinoma and breast cancer (Ohta et al, 1999; Tsurusaki et al,
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Table 3 Univariate and multivariate analysis with respect to lymph nodes metastasis 
Univariate Multivariate 
Variable Comparison Odds ratio P value 95% confidence interval Odds ratio P value 95% confidence interval 
Histological cell type SCC : ADE – NS 
Tumour size (cm) ≤4 : >4 4.3 P = 0.026 1.192–15.409 – NS 
Stromal invasion ≤ 2/3 : > 2/3 15.8 P = 0.011 1.892–132.521 – NS 
Parametrial invasion Negative : Positive 4.5 P = 0.018 1.295–15.635 – NS 
Vaginal invasion Negative : Positive – NS 
LVS involvement Negative : Positive 7.4 P = 0.015 1.468–37.185 – NS 
VEGF-C mRNA Negative : Positive 7.1 P = 0.007 1.720–29.467 6.7 P = 0.029 1.208–35.582 
SCC, squamous cell carcinoma; ADE, adenocarcinoma; LVS, lymph-vascular space: NS, not significant. 
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Figure 2 (A) Disease-free survival curves of 75 patients with invasive
cervical cancer according to VEGF-C mRNA expression. (B) Disease-free
survival curves of 53 patients with stage Ib–IIb cervical cancer underwent
radical hysterectomy and pelvic lymphadenectomy according to VEGF-C
mRNA expression 
100
80
60
40
20
0
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
VEGF-C(-) (n = 26)
VEGF-C(+) (n = 27)
P = 0.049
0 1 02 03 04 05 06 0
Post-operative months1999; Akagi et al, 2000; Gunningham et al, 2000). Accordingly,
VEGFR-2 may not be a primary receptor of VEGF-C in these
tumours. In fact, VEGF-C displays greater affinity for VEGFR-3
than for VEGFR-2. Furthermore, proteolytic processing of VEGF-
C generates several VEGF-C forms possessing increased activity
toward VEGFR-3; however, the fully processed VEGF-C can acti-
vate VEGFR-2 (Joukov et al, 1997). 
The current study also indicated that patients with VEGF-C
mRNA expression exhibit poorer prognoses than those lacking
VEGF-C mRNA expression. VEGF-C, which is strongly corre-
lated to pelvic lymph node metastasis, may influence prognosis.
However, VEGF-C mRNA expression was not an independent
prognostic factor among our study population. Consequently,
VEGF-C expression dose not appear to be a useful prognostic
factor in cases of cervical cancer. VEGF-D, which is 48% identical
with VEGF-C, may also bind to and activate VEGFR-3 (Yamada
et al, 1997). Consequently, VEGF-D might play a crucial role in
lymph node metastasis in addition to influencing prognosis.
Further investigation is necessary in order to clarify this issue. 
In conclusion, our findings indicate that VEGF-C expression is
involved in the promotion of lymph node metastasis in cervical
cancer. Furthermore, examination of VEGF-C expression in
biopsy specimens may be useful as a predictor of pelvic lymph
node metastasis. 
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